Trial Profile
Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Triptorelin (Primary) ; Zoledronic acid (Primary) ; Tamoxifen
- Indications Early breast cancer; Osteoporosis
- Focus Therapeutic Use
- Acronyms HOBOE
- 06 Mar 2023 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified March 2021).
- 03 Mar 2021 Planned End Date changed from 1 Mar 2019 to 1 Nov 2022.
- 03 Mar 2021 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2021.